Your AI-Trained Oncology Knowledge Connection!
The FDA recently expanded the drug label for carfilzomib (Kyprolis), which is now approved in combination with dexamethasone or with lenalidomide plus dexamethasone for patients with relapsed or refractory disease who have received one to three lines of therapy.
A laboratory study found that the Hhex protein is overexpressed in acute myeloid leukemia cells and is necessary for their propagation but not for normal myelopoiesis.
Most adolescent and young adult survivors of Hodgkin lymphoma did not receive the recommended care within the first year post-treatment, according to a study.
A laboratory study showed that peroxisome proliferator-activated receptor gamma agonists such as pioglitazone could help treat chronic myeloid leukemia patients who are resistant or otherwise unresponsive to treatment with tyrosine kinase inhibitors.
A new study has shown that dinaciclib disrupted homologous recombination function and led to cell death in multiple myeloma cell lines when combined with the PARP1/2 inhibitor ABT-888.
Researchers have identified several factors that may help to predict the progression of vertebral fractures and future fractures in patients with multiple myeloma.
An oncology pharmacist-managed program significantly increased adherence to tyrosine kinase inhibitor therapy among patients with chronic myeloid leukemia.
In this interview we discuss results of the CALGB 10603 RATIFY trial of midostaurin for acute myeloid leukemia presented earlier this month at ASH.
More than half of hematologists providing care to patients with hematologic malignancies reported initiating end-of-life conversations too late in the course of the patient’s disease.
The success of allogeneic HCT in patients with AML varied among those with complete remission and minimal residual disease positivity vs negativity.
Ponatinib offered a better overall survival for chronic myeloid leukemia patients in chronic phase compared with allogeneic stem cell transplantation.
A case series of three individuals suggests that there may be a causal relationship between chemotherapeutic treatments for germ cell tumors and the subsequent development of chronic myeloid leukemia.
Real-time classification can identify a previously unrecognized subset of high-risk patients with childhood B-cell acute lymphoblastic leukemia who have excellent chances for cure without further intensification of treatment.
Single-agent ibrutinib resulted in significantly improved outcomes for older patients with chronic lymphocytic leukemia, compared with chlorambucil treatment.
Patients with relapsed or refractory CLL had significant delays in progression and death when idelalisib was added to bendamustine and rituximab.
Patients with relapsed/refractory multiple myeloma continue to have deep and durable responses to daratumumab plus lenalidomide/dexamethasone.
The oral BCL-2 inhibitor venetoclax elicited a high rate of response from patients with high-risk relapsed or refractory chronic lymphocytic leukemia with 17p deletion.
Children with acute lymphocytic leukemia and their parents commonly over-report the amount of daily oral chemotherapy the child takes to treat the most common blood cancer in children.
Breast cancer survivors with therapy-related leukemia were found to have personal and family histories that suggested an inherited risk for cancer.
Chimeric antigen receptor T cells can eradicate large burdens of multiple myeloma, according to a new study presented at ASH.
Genetic variants increase the risk of osteonecrosis in children under age 10 with acute lymphoblastic leukemia.
Researchers have identified a genetic variant, 2R thymidylate synthase polymorphism, that is associated with an increased risk for avascular necrosis in children with ALL.
In this interview we discuss the role of the tumor microenvironment in Hodgkin and non-Hodgkin lymphoma and research that seeks to disrupt and target this environment as a means of treatment.
Ahead of the 57th ASH Annual Meeting & Exposition, December December 5–8, 2015, Nitin Jain, MD, discusses the cost burden associated with targeted therapy use in the CLL population.
Ahead of the 57th ASH Annual Meeting & Exposition, December 5–8, 2015, Jeffrey Tyner, PhD, discusses his latest research on screening tumor cells derived from cancer patients to help guide better treatment decisions.
